How Do Peptides Work?

Many peptides work by acting as molecular messengers. They bind to receptors on the surface of cells or, in some cases, influence signaling pathways inside the cell. Once that binding happens, the cell responds by changing gene expression, releasing other molecules, altering inflammation, or shifting metabolic activity.

This is why peptide therapy is often described as targeted. The peptide is not simply floating through the body causing random effects. It is meaningful because it interacts with a specific biologic system, even if the downstream results can still be complex.

Peptides are often fragile molecules. Many are degraded quickly by enzymes in the stomach or bloodstream, so the route of delivery can determine whether enough of the compound reaches the relevant tissue. That is why subcutaneous injection is so common: it bypasses the digestive tract and improves delivery for many peptides.

Some peptides have unusual delivery advantages. BPC-157 is discussed in the literature as having oral stability that most peptides do not. Semax is commonly discussed in relation to intranasal delivery because that route aligns with its neurologic use case. GHK-Cu is often topical when the target is skin or hair.

• Subcutaneous delivery is common because it avoids first-pass digestive breakdown.
• Intranasal delivery can be useful for neurologic or central nervous system targets.
• Topical delivery makes sense when the target tissue is the skin or scalp.

Bioavailability describes how much of a compound actually reaches circulation or the intended tissue in an active form. For many peptides, oral bioavailability is poor because stomach acid and digestive enzymes break them down before they can do much.

That is one reason peptide therapy often involves injections, even when people would clearly prefer a pill. The delivery method is not just a convenience question. It is often what makes the therapy biologically plausible in the first place.

Small molecules such as aspirin or metformin are usually compact, chemically stable, and often orally available. Biologics such as monoclonal antibodies are much larger and highly specific, but typically more complex to manufacture and deliver. Peptides sit between those two categories.

That middle ground helps explain both the opportunity and the challenge. Peptides can be more targeted than many small molecules, but they are often less stable and less convenient than pills. They may be easier to work with than full-scale biologics, but they still demand careful handling and dose discipline.

When someone asks how peptides work, the best answer is that they work through biology, not magic. The therapy depends on receptor binding, signaling cascades, tissue distribution, and evidence for a real effect in the intended indication.

That is also why different peptides feel so different in practice. A regenerative peptide, an antimicrobial peptide, a cognitive peptide, and a metabolic peptide may all be called peptides while behaving like entirely different therapies once they enter the body.